EUVIMEDEUVIMED entdecken
Open Access

MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1/anti-TGF-β in squamous cell carcinomas with enhanced CD8 T cell memory-driven response

Hanne T Lind, Spencer C Hall, Alexander A Strait, Jack B Goon, John D Aleman, Samantha M Y Chen, Sana D Karam, Christian D Young, Jing H Wang, Xiao-Jing Wang

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2024.217347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Hanne T Lind und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California, Davis, CA, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Transforming Growth Factor beta, Up-Regulation, B7-H1 Antigen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, BLRD VA, NIDCR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiation therapy (RT), a mainstay treatment for head and neck squamous cell carcinoma (HNSCC), kills cancer cells and modulates the tumor immune microenvironment. We sought to assess the effect of RT in combination with PD-L1/TGF-β dual blockade in squamous cell carcinomas (SCC) and analyze the underlying mechanisms. We transplanted mouse SCC cells derived from keratin-15 (K15) stem cells harboring KrasG12D/Smad4-/- mutations into syngeneic recipients and irradiated tumors followed by PD-L1/TGF-β dual blockade. We identified a responder line and a non-responder line to this combination therapy. Responder hosts eradicated SCCs by the combined therapy and rejected re-transplanted SCC cells 6 months post tumor eradication, which correlated with clonotype expansions of splenic CD8 T cells and effector memory gene expression identified by single cell sequencing of TCR and transcriptomes, respectively. Mechanistically, RT upregulated MHC-I (major histocompatibility complex I) and its transcriptional regulators including NLRC5, in SCCs of the responders but not non-responders. These data are consistent with the TCGA HNSCC database in which NLRC5 correlated to MHC-I genes and CD8 T cell gene expression. Functional contribution of MHC-I to PD-L1/TGF-β blockade response was confirmed by knocking out beta-2-microglobulin in responder cells that attenuated the response to the same therapy. Thus, the therapeutic effectiveness appeared to largely depend on cancer-cell MHC-I expression, triggering CD8 T cell effector memory-driven responses against tumor cell antigens. Identifying the differential RT response to MHC-I induction may serve as a predictive marker for stratifying patients that are most likely to benefit from this combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesTransforming Growth Factor betaUp-RegulationB7-H1 AntigenImmunologic MemoryAnimalsMiceTumor MicroenvironmentHistocompatibility Antigens Class IHumansImmune Checkpoint InhibitorsCell Line, TumorSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsCarcinoma, Squamous Cell

Stichwörter der Autor:innen

ImmunotherapyMHC class IPD-L1RadiotherapySquamous cell carcinomaT cellTGF-β

Substanzen

Transforming Growth Factor betaB7-H1 AntigenHistocompatibility Antigens Class IImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pathology, University of California, Davis, CA, USA.
  • Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Radiation Oncology, Washington University in St. Louis, School of Medicine, MO, USA.
  • UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, Department of Immunology, University of Pittsburg, Pittsburgh, PA, USA.
  • Department of Pathology, University of California, Davis, CA, USA; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; VA Northern California Health Care System, Sacramento, CA, USA…

Förderung

  • NCI NIH HHS
  • BLRD VA
  • NIDCR NIH HHS
  • Israel National Road Safety Authority
  • National Institutes of Health
  • US Department of Veterans Affairs

Zitieren

APA

Lind, H. T., Hall, S. C., Strait, A. A., Goon, J. B., Aleman, J. D., Chen, S. M. Y., Karam, S. D., Young, C. D., Wang, J. H., & Wang, X. J. (2025). MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1/anti-TGF-β in squamous cell carcinomas with enhanced CD8 T cell memory-driven response. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217347

Vancouver

Lind HT, Hall SC, Strait AA, Goon JB, Aleman JD, Chen SMY, et al. MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1/anti-TGF-β in squamous cell carcinomas with enhanced CD8 T cell memory-driven response. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217347

BibTeX
@article{Lind2025,
  author = {Lind, Hanne T and Hall, Spencer C and Strait, Alexander A and Goon, Jack B and Aleman, John D and Chen, Samantha M Y and Karam, Sana D and Young, Christian D and Wang, Jing H and Wang, Xiao-Jing},
  title = {MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1/anti-TGF-β in squamous cell carcinomas with enhanced CD8 T cell memory-driven response},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2024.217347}
}
Kostenlos starten →